These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25185167)

  • 1. Beleodaq approved for rare lymphomas.
    Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
    Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belinostat: first global approval.
    Poole RM
    Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat approved for multiple myeloma.
    Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326
    [No Abstract]   [Full Text] [Related]  

  • 5. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belinostat for the treatment of peripheral T-cell lymphomas.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 10. Vorinostat.
    Grant S; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
    [No Abstract]   [Full Text] [Related]  

  • 11. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Thaler F
    Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new agents for peripheral T-cell lymphoma.
    Ito Y; Makita S; Tobinai K
    Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belinostat (Beleodaq) for peripheral T-Cell lymphoma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988963
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
    Zirlik K; Nashan D; Veelken H
    Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in cancer treatment with histone deacetylase inhibitor].
    Dong M; Hu XS; Chen SS; Xing PY; Feng FY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):481-5. PubMed ID: 24257296
    [No Abstract]   [Full Text] [Related]  

  • 20. Vorinostat approved for rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.